Mucosis B.V. develops prophylactic vaccines using a novel adjuvant platform that enables a more natural immune response as well as a broad base of protection.
The lead product of Mucosis, FluGEM™, is an influenza vaccine for the elderly that provides extra protection by boosting local (mucosal) immunity. This vaccine can be delivered via the nose as well as by injection.
Current product development stage: phase I clinical trials.
